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A common-source outbreak of fulminant hepatitis B in hemodialysis
patients induced by precore mutant. From September 9 to October 3,
1994, five patients on maintenance hemodialysis in a dialysis unit in Tokyo
contracted hepatitis B virus (HBV) infection successively, and four of
them died of fulminant hepatitis. The unit treated 181 patients three times
a week on eight shifts, and all five afflicted patients were on the same shift
along with 27 other patients. HBV DNA clones from the hepatitis patients
had a point mutation converting codon 28 in the precore region to a stop
codon, which aborts the synthesis and secretion of hepatitis B e antigen,
and showed a sequence similarity of >99.5% within 645 base pairs
covering the X gene and precore region. There were two HBV carriers
with antibody to hepatitis B e antigen who were receiving hemodialysis on
the same shift. HBV DNA clones from one of them had the stop codon 28
in the precore region, and a sequence similarity of >99.7% to those from
the five patients. Based on these results, it was deduced that the fulminant
HBV strain was transmitted from the carrier to five patients, and resulted
in the death of four. The outbreak indicates that immunocompromised
hosts like hemodialysis patients can develop fulminant hepatitis B if and
when they are infected with extremely virulent HBV strains.
Patients on maintenance hemodialysis and staff members in
care of them are at high risk of infection with hepatitis B virus
(HBV), because the patients need regular treatments with shared
devices and occasionally receive transfusions. As a consequence,
many epidemics of hepatitis B have occurred in hemodialysis
centers [1—4]. Hemodialysis patients, however, have a clinical
course of HBV infection remarkably different from that of healthy
staff members [1, 4]. Severe acute disease is induced in staff
members which usually resolves with the clearance of HBV, while
patients tend to contract persistent infection with mild clinical and
biochemical manifestations.
Since patients with chronic renal failure who are on mainte-
nance hemodialysis have compromised immune responses [5, 61,
they would have attenuated disease on the one hand and fail to
clear infection on the other. Heightened immune responses to
HBV-associated antigens have been reported commonly in pa-
tients with fulminant hepatitis B [7, 8], which are lacking in
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hemodialysis patients. Hemodialysis patients infected with HBV
are typically positive for hepatitis B e antigen (HBeAg) [91 that is
rarely associated with fulminant strains [10—12], giving a possible
account of the rare occurrence of fulminant hepatitis B in this
population.
The precore region and the core (C) gene of HBV code for the
precursor of HBeAg made of 212 amino acids [13, 14]. The
precursor loses amino-terminal 19 amino acids and carboxyl-
terminal 34 amino acids co-translationally [15, 161, and becomes
HBeAg to be secreted into the circulation. The precore region
codes for a signal peptide of 19 amino acids, which guides the
HBeAg precursor to the endoplasmic reticulum, and an addi-
tional 10 amino acids that makes the amino-terminus of HBeAg
[13, 14, 16].
It has become increasingly evident that most, if not all, cases of
fulminant hepatitis B are induced by HBV variants with mutations
in the precore region that prohibit the synthesis and secretion of
HBeAg [10—12]. By far the most frequent mutation in the precore
region is a point mutation from G to A at nucleotide (nt) 1896,
which converts codon 28 for tryptophan to a stop codon for an
HBeAg-minus phenotype [17, 18].
Here we report on an outbreak of fulminant hepatitis B in a
hemodialysis center in Tokyo that involved four patients who had
fatal outcomes. Another patient contracted acute severe hepatitis
B and recovered. The five patients were deduced to have received
a fulminant HBV strain, with the G-to-A mutation at nt 1986 in
the precore region, which had originated in an HBV carrier with
antibody to HBeAg (anti-HBe) who were receiving hemodialysis
on the same shift as them.
Methods
Patients and staff members of a Tokyo hemodialysis center were
studied. The unit had 35 dialysis beds on the third floor and 26
beds on the fourth floor, and treated 181 patients three times a
week on eight shifts. Patients on the same shift received hemodi-
alysis in a group, and were rarely transferred to the other groups
on different shifts. The center had 86 staff members, of whom 18
were doctors, 25 nurses, 10 technicians, and 33 engaged in the
other jobs not directly in contact with patients.
Hepatitis B surface antigen (HBsAg) and the corresponding
antibody (anti-HBs) were determined by hemagglutination with
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Fig. 1. A map of HBV DNA with transcripts and
products of PCR amplification. The X gene and
the core gene with the precore region are
indicated by boxes with arrow heads. Two 3.5-
kb mRNA5 are shown in the middle which have
start positions within the basic core promoter
[25] indicated by a box. Triangles indicate
positions of direct repeats (DR1 and DR2).
Two lines with arrowheads on both sides at the
bottom represent HBV DNA fragments
amplified by polymerase chain reaction for
sequencing. Nucleotides are numbered from the
unique EcoRl site of the HBV genome [221.
commercial kits (MyCell, Institute of Immunology Co., Ltd.,
Tokyo, Japan, and AUSZYME II, Abbott Laboratories, North
Chicago, IL, USA) and HBeAg as well as anti-HBe by enzyme
immunoassay (HBeAg/Ab EIA, Institute of Immunology Co.).
Subtypes of HBsAg were determined by enzyme immunoassay
(HBsAg SUBTYPE EIA, Institute of Immunology Co.), and 1gM
antibody to hepatitis B core antigen (anti-HBc) by enzyme
immunoassay (CORZYME-M, Abbott Laboratories). Antibody
to hepatitis delta virus was determined by radioimmunoassay with
commercial kits (Anti-Delta RIA, Abbott Laboratories), 1gM
antibody to hepatitis A virus by enzyme immunoassay
(HAVAB-M, Abbott Laboratories), and antibody to hepatitis C
virus by enzyme immunoassay with a second-generation kit (Or-
tho Diagnostic Systems, Tokyo, Japan).
HBV DNA was determined and semiquantified by polymerase
chain reaction (PCR) with nested primers deduced from the S
gene by the method described elsewhere [19, 20]. In brief, serum
(100 pA) was treated with proteinase K and sodium dodecyl
sulfate, and nucleic acids were extracted by phenol/chloroform
and precipitated with ethanol. HBV DNA sequences were then
amplified by PCR with nested primers. The sequence of a
3'-terminal part of the X gene and precore region (263 base pairs
[bp], nt 1679-1941), as well as that of the entire S gene (822 bp, nt
64-885), was determined by the methods reported previously [20,
21]; nt was numbered from the unique EcoRI site of the HBV
genome [22].
For the amplification of an HBV DNA fragment containing the
entire X gene, the first round of PCR was performed with primer
$022 (sense, 5 '-TCCTCTGCCGATCCATACTG-3' [nt 1254-
1273]) and $038 (antisense, 5 '-AAAGTTGCATGGTGCTGGTG-
3' [nt 1804-18231) for producing 570-bp fragments, and the second
round with $026 (sense, 5'-TCTGCCGATCCATACTGCGG-3'
[nt 1257-1276]) and $039 (antisense, 5'-ATGGTGCTGGTGAA-
CAGACC-3' [nt 1796-1815]) for 559-bp fragments. The sequence
of precore region was determined on five independent clones, and
those of the X and S genes on three independent clones that had
been propagated from each serum. The nucleotide sequences of
the plus and minus strands were determined by ALF AutoRead
DNA sequencing kit (Pharmacia LIKE Biotechnology, Uppsala,
Sweden).
The products of PCR amplification, covering the X gene and
precore region, are indicated in Figure 1 in relation to various
elements of HBV DNA and mRNAs.
Results
The outbreak
Within a month in the fall of 1994, five patients successively
developed clinical symptoms of acute hepatitis. The first patient
(Patient 1) developed fever and anorexia on September 5, and was
admitted on September 9 when she was found to be positive for
HBsAg. Patient 2 was admitted on September 12 due to fever and
jaundice, and tested positive for HBsAg. This alerted personnel in
the hemodialysis center to screen patients and staff members for
HBsAg, and on September 19 three additional patients were
found to be infected. The initial subjective symptom was fever in
all of them, and the three patients were hospitalized two to four
days later. Table 1 shows transaminase levels, HBsAg and 1gM
anti-HBc titers of the five patients on the day of admission, as well
as their clinical diagnosis and outcome.
Four of the five patients (Patients 2 to 5) developed fulminant
hepatitis with severe hepatic encephalopathy and marked elonga-
tion of prothrombin time, and died from 2 to 13 days after the
admission. Autopsies performed on three of them found marked
liver atrophy, and many hemorrhagic foci were observed in the
liver.
The other patient (Patient 1) contracted acute severe hepatitis
with serum bilirubin peaking at 20.4 mg/100 ml, and recovered
fully within a month. She lost HBsAg and seroconverted to
anti-HBs a month after the admission.
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Table 1. Clinical and serological profiles of the five hemodialysis patients who contracted HBV infection in the outbreak
Patient's
age and
sex
Duration
of dialysis
years
Date of
admission
ALT
U/liter
HB5Ag
(COla)
1gM
anti-HBc
(COIfl) Diagnosis Outcome
1 54F 14 9/09/94 5,040 26.1 7.4 severe acute Survived
2 34F 9.2 9/12/94 5,980 207.2 7.2 fulminant Died ( 9/17/94)
3 41F 17.6 9/25/94 14,826 >30 7.0 fulminant Died (10/01/94)
4 66M 3.3 9/26/94 6,615 >30 6.9 fulminant Died (9/28/94)
5 82M 10 10/03/94 5,460 31.6 4.6 fulminant Died (10/16/94)
a Cut-off index in enzyme immunoassay; values >1.0 indicate positive
All the five patients were negative for HBsAg by tests per-
formed six months before (March 14, 1994). The later diagnosis of
fulminant or acute severe hepatitis B in them was based on the
detection of HBsAg and high-titer 1gM anti-HBc in their sera, and
lack of serum markers of the other hepatitis viruses, such as 1gM
antibody to hepatitis A virus as well as antibodies to hepatitis
delta virus and hepatitis C virus. Characteristically, all four
patients with fulminant hepatitis had high HBsAg titers in their
sera on the day of admission, and all of them had the HBsAg of
subtype adw. Neither HBeAg nor anti-HBe was detected in the
four patients with fulminant hepatitis (Patients 2 to 5). The
patient with severe acute hepatitis (Patient 1) did not have
HBeAg or anti-HBe a week after the onset; anti-HBe was
detected in her serum when she was tested again 13 days
thereafter.
HBJ/ infection in the other patients and staff members of the
hemodialysis center
For the purpose of identifying the source of infection and
preventing further spreading, HBsAg and anti-HBs were screened
from September 14 to October 4. Tests were completed in 179
hemodialysis patients (except for Patients 1 and 2 who were
infected and admitted at that time) and by 71 (83%) staff
members, including all doctors, nurses and technicians in the
hemodialysis center. Patients 3 to 5 were found to be infected with
HBV at the screening.
There were three hemodialysis patients who tested positive for
HBsAg on a routine screening on March 14, 1994. Hereafter they
are referred to as Carriers 1 to 3; they all kept HBsAg at the
screening six months later. None of the 71 staff members were
positive for HB5Ag, and anti-HBs were detected in 19 (27%) of
them.
A total of 181 patients received hemodialysis three times a week
in eight groups on separate shifts. Patients 1 to 5 were in the same
group along with 27 other patients for 16 months or longer prior
to the hepatitis outbreak. That group included Carrier 1, a
69-year-old male, and Carrier 2, a 53-year-old male. Carrier 3, a
62-year-old male, was in another group of 27 patients on a
different shift; however, he received hemodialysis in the same
group as Patients 1 to 5 during August 1994.
Carriers 1 to 3 were all negative for HBeAg and positive for
anti-HBe. The subtype of HB5Ag was adw in Carrier 1 as in
Patients 1 to 5, while it was adr in Carriers 2 and 3. Receiving
hemodialysis in the same group as Patients ito 5 for a long period
of time, as well as having the same HBsAg subtype (adw), led us
to believe that Carrier 1 was the most likely source of HBV
infection in the outbreak.
Aside from Carriers 1 to 3, an additional carrier received
hemodialysis in the same unit. He was 70 years old and tested
positive for HBsAg and HBeAg on March 14, 1994. He developed
acute cardiac failure due to aortic and tricuspid insufficiency as a
sequel of rheumatic fever, and was transferred to another hospital
on May 6, 1994. During April 1994, still another carrier received
hemodialysis by the referral from other dialysis unit. He was
positive for HB5Ag and anti-HBs; serum samples were not
available from these two carriers for further testing.
Nucleotide sequences of HBV DNA clones from Patients 1 to 5
and Carriers 1 to 3
The sequence of precore region was determined on five clones
each, and that of the X and S genes on three clones each,
propagated from sera of Patients 1 to 5 and Carriers 1 to 3. The
eight consensus sequences of a 3'-terminal part of the X gene and
the precore region, from the five patients and three carriers, are
compared in Figure 2, along with the sequence of an HBV strain
of subtype adw.
HBV DNA clone from Carrier 1 had a point mutation from G
to A at nt 1896 converting codon 28 in the precore region for
tryptophan (T GG) to a stop codon (T AG), and another G-to-A
mutation at nt 1899 converting codon 29 for glycine (G GC) to
aspartic acid (G AC). The same two mutations were possessed by
HBV DNA clones from Patients ito 5. Clones from Carrier 3 had
the G-to-A mutation at nt 1986 only; however, those from Carrier
2 lacked these mutations. All clones from Carrier 1 and Patients
ito 5 had A-to-C point mutation at nt 1726, within the 3'-terminal
sequence of the X gene, and T-to-C point mutation at nt 1847,
representing the first letter of codon 12 in the precore region.
These two point mutations were not seen in clones from Carriers
2 and 3.
Scattered point mutations were found in clones from Carriers 2
and 3, which were not shared by clones from Carrier 1 or Patients
I to 5. Clones from Carrier 2 had A-to-T point mutation at nt 1762
within the second AT-rich region in the basic core promoter
[TTAAA (nt 1758-1762)1 and G-to-A mutation at nt 1764, 2 bp
downstream of it, which were not seen in clones from the other
carriers or patients.
Table 2 shows the sequence similarity among HBV DNA clones
from Patients 1 to 5 and Carriers I to 3. Within the entire X gene
and precore region, sequences of Patients 1 to 5 were similar to
each other in 99.5 to 100%, and to that of Carrier 1 in 99.7 to
99.8%. They were similar only by 91.8 to 92.9% to sequences of
Carriers 2 and 3. A close similarity was also observed in the S gene
sequences between Patients 1 to 5 and Carrier 1.
Small but significant differences in HBV DNA clones from
Patients 1 to 5 and Carrier 1, however, indicated heterogeneous
HBV populations. They were infected with at least three distinct
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Fig. 2. Nucleotide sequences ofa part of the Xgene and the entire precore region of IIBVDNA clones from the three carriers and five patients. The consensus
nucleotide sequence of HBV (subtype adw) of an HBeAg-plus phenotype [22] is indicated at the top. Five clones each were obtained from carriers and
patients. All the five clones from each carrier or patient had the identical sequence within 246 bp in comparison (primer sequences at both ends
excluded). The second AT-rich region in the basic core promoter is overlined, and ATG initiation codon of the precore region is boxed.
Table 2. Similarity in the nucleotide sequence among HBV DNA clones from the five patients in the outbreak and the three carriers who were
suspected of transmitting infection to them
The X gene and precore region
[645 base pairs (nucleotides 1277—1921)]
The S gene
[782 base pairs (nucleotides 84—865)]
Patients' Carrier I Carrier 2 Carrier 3 Patientsa Carrier 1 Carrier 2 Carrier 3
Patient 1 99.7—100 99.7 91.8 92.7 98.5—100 99.5 91.8 91.2
Patient 2 99.7—99.8 99.8 91.9 92.9 98.6—99.6 99.6 91.9 91.3
Patient 3 99.5—99.8 99.7 91.8 92.7 98.5—100 99.5 91.8 91.2
Patient 4 99.7—400 99.7 91.8 92.7 99.0—99.5 99.0 91.4 90.8
Patient 5 99.5—99.8 99.8 91.9 92.6 98.5—99.5 98.5 91.7 91.0
Nucleotide sequences of HBV DNA clones from the five patients were compared within indicated regions of the HBV genome among themselves
and against those of the three carriers. Figures represent percent sequence similarity.
a Comparison was made between the sequence of a certain patient and those of the rest of four patients
HBV strains which were distinguished from one another by Unique mutations in the fulminant HBV strain
sequence divergence in the S gene. Of the 18 HBV DNA clones
from them, 11(61%) were of strain I (all 3 clones from Carrier 1 Unique mutations not seen in any reported HBV isolates were
included), 6 (33%) were of strain II, and 1 (6%) was of strain III. detected in HBV DNA clones from Patients I to 5 and Carrier 1
They all had lysine for both codons 122 and 160, which is (Table 3). They were two point mutations within 782 bp (nt 84-
consistent with the subtype adw [23]. 865) including the S gene, and three of those within 645 bp (nt
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Table 3. Unique point mutations shared by 18 HBV DNA clones from
the Carrier 1 and Patients 1 to 5 and amino acid changes induced
by them
Amino acid
changes in
Nucleotide position Point the S, X Amino acid changes
(gene and region) mutation and precore in the P gene
226 (S gene) A — C None Asn399 — His399
777 (5 gene) T — C 11e208 —* Thr208 None
1563 (X gene T — C None None
1565 (X gene) A — G None His825 —* Arg825
1847(Precore) T—C Cys12—Arg12
HBV DNA clones were compared with reported HBV isolates [22]
within 1427 bp [782 bp (nt 84-865) and 645 bp (nt 1277-1921)], and the five
mutations not found in any of them are listed.
1277-1921) including the X gene and precore region. Four of the
five point mutations induced amino acid changes, either in the
products of respective gene and region or in that of the P gene.
Discussion
Until now, two common-source outbreaks of fulminant hepati-
tis have been reported which were caused by HBV variants with a
mutation in the precore region for an HBeAg-minus phenotype.
One of them occurred in a medical center in Israel [11, 24], and
fatally attacked six patients in the same ward within four weeks.
The other happened in a Japanese hospital and involved two
pediatricians and a nurse [10]. Both doctors died of fulminant
hepatitis B, while the nurse recovered from acute hepatitis B. The
HBV strain with this mutation in the precore region converting
codon 28 for tryptophan to a stop codon and incapable of
encoding HBeAg was found in all six Israeli patients [111. In Japan
the HBV strain with a mutation was detected in two doctors and
the nurse, as well as in one of their pediatric patients who carried
HB5Ag and was negative for HBeAg [10]. The identity in nude-
otide sequences of HBV DNA clones from patients in the Israeli
outbreak, and that from three medical staff members and the
pediatric patient in the Japanese outbreak, stands in further
support of the common-source infection with fulminant HBV
strain having the precore mutation [10, 11].
The fulminant hepatitis B in a hemodialysis center in Tokyo
reported here, which resulted in the death of four patients within
a month in the fall of 1994, is a third common-source outbreak
caused by HBV variant with the precore mutation and of an
HBeAg-minus phenotype. Epidemiological analyses were per-
formed on all the 181 patients receiving dialysis in the center and
all 53 doctors, nurses and technicians who were in direct contact
with patients. Sequences of HBV DNA clones were compared
among the five patients and three HBV carriers who had been on
maintenance hemodialysis and who were suspected as the source
of infection. The obtained results pointed to the transmission of a
precore mutant with the stop codon 28 from one of the three
carriers to the five patients.
All three carriers on hemodialysis were positive for anti-HBe,
and the stop codon 28 was detected in two of them. Due to a
>99.0% similarity within the sequence of 1,427 bp in comparison,
the HBV strain in one of the two carriers with the stop codon 28
(Carrier 1) was deduced to be the originator of the outbreak. The
strain from the other carrier (Carrier 3) with the stop codon 28
showed a similarity of only <92%, and lacked the stop codon 29
which was possessed in common by HBV DNA clones from
Carrier 1 and the five patients involved in the outbreak. HBV
DNA clones from the remaining carrier (Carrier 2) did not have
the stop codon 28 or any other mutations in the precore region to
abort the synthesis and secretion of HBeAg [181, despite the fact
that he was positive for anti-HBe. However, they had point
mutations in the X gene which would prohibit the transcription of
the coding region for HBeAg precursor.
As illustrated in Figure 1, the basic core promoter spans nt
1742-1849, straddling the X gene and precore region [25]. It has
three AT-rich regions [20, 26, 27], which would interact with
TATA binding protein [28] for the transcription of precore and
pregenome—core/polymerase mRNAs by host RNA polymerases.
Mutations in the second AT-rich region (nt 1758-1762) have been
proposed to interfere with the transcription of precore mRNA
and prohibit the expression of HBeAg at the transcriptional level
[20].
A-to-T point mutation at nt 1762 in the second AT-rich region,
as well as G-to-A point mutation at nt 1764, was found in all
clones from Carrier 2 (Fig. 2). Such a pair of point mutations is
frequently seen in HBV DNA clones from carriers who had
seroconverted from HBeAg to anti-HBe [20] and patients with
fulminant hepatitis B that did not have mutations in the precore
region despite an HBeAg-minus phenotype [29]. Since the G-to-A
point mutation at nt 1896 in the precore region was not seen in
HBV DNA clones from Carrier 2, the A-to-T mutation at nt 1762
in the second AT-rich region, possibly in concert with the G-to-A
point mutation 2 bp downstream, would have prohibited encoding
HBeAg at the transcriptional level [20]. This may account for why
this carrier was positive for anti-HBe despite the lack of any
precore mutations in his HBV DNA clones.
The outbreak of fulminant hepatitis in the hemodialysis center
in Tokyo would be unique in that it exclusively involved hemodi-
alysis patients, and that a minor, but substantial sequence heter-
ogeneity was observed in the HBV with which they were infected.
Due to compromised immune responses [5, 6], hemodialysis
patients usually have a mild disease and prolonged course;
typically they continue to carry HBV without clinical symptoms
and with little elevation in transaminase levels [1, 2]. This is in
sharp contrast with HBV infection in the staff members of dialysis
units, who have acute and often severe hepatitis. HBV infection
subsides in the majority of them, while a few can come down with
fulminant hepatitis.
It may come as a surprise that the four patients with fulminant
hepatitis in the present report had high HBsAg titers in their sera.
Because exaggerated immune responses to HBV-associated anti-
gens are common in the patients with fulminant hepatitis B [7, 8],
HBsAg is not detectable in many of them at the presentation;
their disease can be diagnosed only by high-titer 1gM anti-HBc
[30]. The detection of high-titer HBsAg in hemodialysis patients
with fulminant hepatitis in the Tokyo outbreak suggests that viral
factors, rather than heightened immune responses, had a major
role in the manifestation of fulminant hepatitis in these patients.
Two viral factors influencing the disease severity are postulated:
the virulence and load of virus. Undoubtedly the fulminant HBV
strain in the Tokyo outbreak was extremely virulent. It incurred
death in four of the five hemodialysis patients who were infected,
and it had the mutation in the precore region which aborts the
synthesis and secretion of HBeAg, as in most fulminant strains
reported [10—12]. In addition, it had unique mutations not seen in
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any HBV strains reported, some of which might have been
associated with an enhanced virulence. Such a view must be
evaluated by transfecting cultured cells with this fulminant strain
for estimating the efficiency of mRNA/pregenome synthesis and
the production of viral proteins.
There are some lines of evidence to indicate that the initial viral
load would have been extraordinarily high in the Tokyo outbreak
of fulminant hepatitis in hemodialysis patients. Although HBV
DNA clones from five patients involved (Patients 1 to 5) and the
implicated transmitter (Carrier 1) were very similar, with identical
point mutations and sharing >99% of the sequence of 1,427
nucleotides, at least three different strains were identified among
them. A single strain represented all the three clones from the
implicated carrier, thereby indicating that this strain would be the
major population of HBV in the transmitter. That particular
strain, however, accounted for only one of three clones from one
patient, and was not seen in any of three clones from another. This
is not the case for transmission by small-dose inocula, in which the
perfect sequence identity is observed in HBV DNA clones from
both patients and transmitters [10]. Transmission of such a wide
variety of HBV population from the Carrier 1 to the five patients
would have been accomplished by large-dose inocula with a high
viral load, which were most likely introduced during the hemodi-
alysis sessions.
The Tokyo outbreak of fulminant hepatitis warns that hemodi-
alysis patients can foster highly virulent HBV strains possibly
owing to their compromised immune responses, which may spread
among fellow patients and to medical personnel in their care. It
alerts staff members to be prepared for any such accidents by
receiving hepatitis B vaccines, a procedure which has not been
widely accepted. Traditionally and notoriously, physicians do not
take good care of themselves. Although they all are aware of
hepatitis B vaccine, less than a quarter of the population is willing
to receive it [311. This prophylactic measure must be taken to
protect hemodialysis patients, who are at much higher risk for
HBV infection than staff members. Due to compromised immune
responses, patients do not respond sufficiently to hepatitis B
vaccines for raising protecting antibodies. Fortunately, this disad-
vantage may be circumvented by low-dose interleukin-2, which is
reported to be effective in increasing the response to hepatitis B
vaccine in hemodialysis patients [32, 331.
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